1 week Ago By ABMN Staff
SI-BONE, Inc. ( NASDAQ:SIBN – Get Free Report ) has received a consensus rating of “Buy” from the six ratings firms that are covering the company, MarketBeat reports. Six analysts have rated the stock with a buy rating.
The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $23.00. A number of equities research analysts have weighed in on SIBN shares.
Morgan Stanley decreased their target price on shares of SI-BONE from $21.00 to $19.00 and set an “overweight” rating for the company in a research note on Tuesday, August 6th.
Truist Financial reduced their price objective on SI-BONE from $20.00 to $18.00 and set a “buy” rating for the company in a research report on Tuesday, August 6th.
Finally, Needham & Company LLC dropped their target price on SI-BONE from $27.00 to $19.00 and set a “buy” rating on the stock in a research report on Tuesday, August 6th.
Check Out Our Latest Stock Report on SI-BONE Insider Activity at SI-BONE Hedge Funds Weigh In On SI-BONE Several large investors have recently made changes to their positions in SIBN. Brown Advisory Inc. boosted its position in shares of SI-BONE by 5.
4% during the fourth quarter. Brown Advisory Inc. now owns 4,207,703 shares of the company’s stock worth $88,320,000 after acquiring an additional 214,089 shares during the last quarter.
First Light Asset Management LLC boosted its holdings in shares of SI-BONE by 0.9% during the 4th quarter. First Light Asset Management LLC now owns 2,547,392 shares of the company’s stock valued at $53,470,000 after purchasing an additional 23,299 shares during the last quarter.
Vanguard Group Inc. increased its holdings in shares of SI-BONE by 1.8% in the first quarter.
Vanguard Group Inc. now owns 2,463,501 shares of the company’s stock worth $40,328,000 after purchasing an additional 43,670 shares during the last quarter. Champlain Investment Partners LLC increased its holdings in shares of SI-BONE by 104.
8% in the first quarter. Champlain Investment Partners LLC now owns 2,453,147 shares of the company’s stock worth $40,158,000 after purchasing an additional 1,255,610 shares during the last quarter. Finally, American Century Companies Inc.
lifted its position in shares of SI-BONE by 22.8% in the second quarter. American Century Companies Inc.
now owns 1,986,476 shares of the company’s stock worth $25,685,000 after buying an additional 368,637 shares in the last quarter. 98.11% of the stock is currently owned by hedge funds and other institutional investors.
SI-BONE Trading Down 4.3 % Shares of NASDAQ:SIBN opened at $15.15 on Monday.
SI-BONE has a 1 year low of $11.76 and a 1 year high of $23.25.
The stock’s fifty day moving average price is $15.06 and its 200-day moving average price is $15.06.
The company has a market cap of $631.60 million, a P/E ratio of -13.90 and a beta of 1.
22. The company has a debt-to-equity ratio of 0.22, a current ratio of 9.
17 and a quick ratio of 8.12. SI-BONE ( NASDAQ:SIBN – Get Free Report ) last announced its quarterly earnings results on Monday, August 5th.
The company reported ($0.22) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.
04. SI-BONE had a negative net margin of 27.10% and a negative return on equity of 24.
27%. The firm had revenue of $39.97 million for the quarter, compared to the consensus estimate of $38.
95 million. During the same quarter last year, the firm posted ($0.30) EPS.
Sell-side analysts expect that SI-BONE will post -0.89 earnings per share for the current year. About SI-BONE ( Get Free Report SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally.
It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products. Featured Stories Receive News & Ratings for SI-BONE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SI-BONE and related companies with MarketBeat.com's FREE daily email newsletter .
.
